Radiation Oncology
Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.
Recent Discussions
In clearly resectable pancreatic adenocarcinoma with no arterial or venous involvement, is there a role for neoadjuvant chemotherapy?
There is currently equipoise regarding this question, and the Alliance A021806, a phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer, clinical trial will address it. There is a role in certain subsets of patients without clear vascular involvement regar...
What would be your radiation boost technique and dose levels for adjuvant treatment of endometrial cancer with high-grade disease or aggressive histology if there was a positive margin at the parametrium after TAH+BSO?
I usually consider 50.4 Gy with EBRT followed by an additional 5.4 Gy to the parametrial region. Whether this additional boost helps is not known.
Should methotrexate be stopped prior to radiation therapy if a patient has rheumatoid arthritis?
I have not stopped as dose of MTX for RA is low (7.5 mg) and there is data of CMF with RT for breast cancer with higher dose of MTX showing no significant increase in morbidity.
What volumes and dose would you use for a chest wall recurrence in a patient who had previous mastectomy and completed only a partial prior course of PMRT?
I would treat it like a new course, provided cumulative brachial plexus dose constraints are met.
In a patient with local recurrence of breast cancer after mastectomy, how would you sequence adjuvant treatment after wide local resection?
Endocrine therapy can be given simultaneously with RT without increasing toxicity or decreasing effectiveness, as shown in a randomized French-Swiss trial (Azria et al., PMID 20138810). Toxicities from chemotherapy may be greater and its effectiveness reduced (at least for high-risk patients) when g...
Would you recommend adjuvant radiation to the chest wall and/or regional lymphatics after a resected chest wall recurrence?
Absolutely, would treat chest wall and RNI including IMs in most cases
What dose constraints do you use for the pulmonary vein, pulmonary artery, and superior vena cava for thoracic reirradiation after prior conventional fractionation to a central lung tumor?
In my opinion, the best paper to address this is from Stanford University. The authors describe normal tissue toxicity after thoracic reirradiation. Various dose fractionation schedules were used for both the 1st and 2nd courses of radiation, with dose converted to conventional fractionation (2 Gy e...
What are your institutions' preferences on SBRT vs. histotripsy for treatment of liver metastases?
I'll avoid the institutional political discussion of competing modalities. Like many ablative modalities, there is limited data directly comparing the safety and effectiveness of SBRT. As the new kid on the block, histotripsy has no comparative data that I'm aware of with existing modalities.HistoSo...
How do you treat non-spine bone oligometastases?
Get the MRI. It is proven to reduce inter-observer variability in contouring (Raman et al., PMID 29748100). More philosophically, sometimes you'll see something more, sometimes you won't. But the only way to know is to check. And if this treatment is worth doing, it's worth doing accurately -- espe...
Would you include a seroma in an adjuvant radiation field for post-op endometrial cancer?
The general principle I follow is if I can include it safely, I would. Otherwise, would skip most of it (lymphocele). If lymphocele is the site of positive pathological node, then include it in CTV.